我如何对待成年人Ph+ ALL
1Division of Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Blood
|August 22, 2024
概括
费城染色体阳性急性淋巴细胞白血病 (Ph + ALL) 的结果已通过激素激酶抑制剂 (TKIs) 和免疫治疗得到改善,现在提供75-80%的存活率. 管理复发和治疗持续时间的新挑战正在出现.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 费城染色体 (Ph) 是癌症中一个显著的遗传异常.
- Ph阳性急性淋巴细胞白血病 (Ph+ ALL) 是成人ALL中最常见的遗传亚型.
- 从历史上看,Ph+ALL的预后很差,特别是在老年人中.
研究的目的:
- 讨论成年PH+ALL的不断变化的管理.
- 突出当前的挑战,包括复发和停止治疗.
- 审查化疗,干细胞移植,TKI和免疫治疗的作用.
主要方法:
- 基于案例研究的讨论.
- 审查当前的治疗策略.
- 对治疗结果和挑战的分析.
主要成果:
- 氨酸激酶抑制剂 (TKIs) 和免疫疗法显著提高了Ph + ALL的存活率,达到75-80%.
- 系统化疗和全原干细胞移植仍然是重要的治疗方法.
- 中枢神经系统复发和一般治疗复发存在重大管理困难.
结论:
- 成年Ph + ALL的管理景观已被向疗法和免疫疗法所改变.
- 最佳的患者管理需要解决诸如中枢神经系统复发等挑战,并考虑停止TKI治疗.
- 需要进一步的研究来完善治疗策略,并克服Ph + ALL护理中的新出现的挑战.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K